T-cell immunoglobulin mucin 3 blockade drives an antitumor immune response in head and neck cancer.

MLA

Liu, Jian‐Feng, et al. “T-Cell Immunoglobulin Mucin 3 Blockade Drives an Antitumor Immune Response in Head and Neck Cancer.” Molecular Oncology, vol. 11, no. 2, Feb. 2017, pp. 235–47. EBSCOhost, https://doi.org/10.1002/1878-0261.12029.

APA

Liu, J., Ma, S., Mao, L., Bu, L., Yu, G., Li, Y., Huang, C., Deng, W., Kulkarni, A. B., Zhang, W., & Sun, Z. (2017). T-cell immunoglobulin mucin 3 blockade drives an antitumor immune response in head and neck cancer. Molecular Oncology, 11(2), 235–247. https://doi.org/10.1002/1878-0261.12029

Chicago

Liu, Jian‐Feng, Si‐Rui Ma, Liang Mao, Lin‐Lin Bu, Guang‐Tao Yu, Yi‐Cun Li, Cong‐Fa Huang, et al. 2017. “T-Cell Immunoglobulin Mucin 3 Blockade Drives an Antitumor Immune Response in Head and Neck Cancer.” Molecular Oncology 11 (2): 235–47. doi:10.1002/1878-0261.12029.